HUMAN trial

This project is testing the safety of SAB-142 when given to healthy volunteers and patients with Type 1 diabetes (T1D). It is similar to an approved drug called Thymoglobulin. Thymoglobulin is being studied at doses up to 4.5 mg/kg for potential benefit in people who have T1D. As SAB-142 is a fully human antibody, SAB-142 may have similar benefits for people with T1D without the side effects associated with an animal antibody product.   

What are the benefits of participating?  

If you agree to take part in this study, there will be no direct benefit to you. However, your participation in this study may help develop important scientific knowledge that could contribute to the development of a potential new treatment for T1D. We hope the information learned from this study will benefit patients with T1D in the future. You will be compensated for your time and travel.  

Want to know more?  

To find out more please contact the following people: emiliegarside@veritusresearch.com; adelebarnard@veritusresearch.com or jacksonpetersen@veritusresearch.com